News

WHEN Aimee Chapman began using fat jabs just over a year ago, she never expected to end up in hospital fighting for her life, ...
Novo Nordisk's current product portfolio is well-protected by patents until at least 2030. Click here to see why NVO stock is ...
In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.
A new study led by York University, looking at the health data of nearly 15,000 people enrolled in a medically supervised ...
The drug known as Wegovy is being tested in Canada as a treatment for MASH, formerly known as fatty liver disease. CTV's Pauline Chan has the details.